In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 176 to 200 of 388

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]	Technology appraisal guidance	TBC
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]	Technology appraisal guidance	TBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]	Technology appraisal guidance	TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]	Technology appraisal guidance	TBC
Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]	Technology appraisal guidance	TBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]	Technology appraisal guidance	TBC
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]	Technology appraisal guidance	10 July 2026
Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]	Technology appraisal guidance	TBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]	Technology appraisal guidance	TBC
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]	Technology appraisal guidance	3 September 2026
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]	Technology appraisal guidance	TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]	Technology appraisal guidance	TBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340]	Technology appraisal guidance	TBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]	Technology appraisal guidance	TBC
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]	Technology appraisal guidance	2 December 2026
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]	Technology appraisal guidance	TBC
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]	Technology appraisal guidance	TBC
Managing common infections - antimicrobial prescribing guidelines	NICE guideline	TBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]	Technology appraisal guidance	TBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]	Technology appraisal guidance	TBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]	Technology appraisal guidance	TBC
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]	Technology appraisal guidance	TBC
Melanoma (metastatic) - talimogene laherparepvec [ID508]	Technology appraisal guidance	28 September 2016
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver	Interventional procedures guidance	15 October 2026
Mental health guidelines	NICE guideline	TBC

Results per page

10
25
50
All